Anti-troponin I antibodies in renal transplant patients

Nunes, José Pedro L.; Sampaio, Susana; Cerqueira, Ana; Kaya, Ziya; Oliveira, Nuno

doi:10.1016/j.repce.2014.08.017

Cited by 2 publications

(5 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In renal transplant patients (under immunosuppressive therapy) (41), the presence of an anti-troponin I antibody titre ≥1:80 was not associated with clinical cardiac disease, but was associated with statin therapy status. This find is particularly peculiar, and although possible immunomodulatory statin effects may play a role in the mechanism behind these findings, other explanations (such as chance or a selection bias, as acknowledged by © Annals of Translational Medicine.…”

Section: Discussionmentioning

confidence: 92%

“…Most studies assessed anti-troponin I antibodies (9,12,14,(39)(40)(41)(42)(45)(46)(47)(48)50,51,(53)(54)(55)(56)(57)(58), whereas anti-troponin T antibodies were assessed in only 16% (n=1,636) of individuals (11,43,44,49,52) (including 993 individuals where both types of autoantibodies were evaluated) (11,44,49).…”

Section: Resultsmentioning

confidence: 99%

“…As put forward by Doesch et al, different risk factors play a role in distinct cardiac disorders (namely DCM and ICM) (12), a fact that has been previously highlighted (73). Also, the fact that medication could affect its values is worth considering in future research (41,48). As such, only with large patient groups with similar characteristics can solid conclusions be reached on such a complex issue.…”

Section: Study Limitationsmentioning

confidence: 90%

“…One study presented data regarding the prevalence of antitroponin I antibodies in a group of 48 renal transplant patients under immunosuppressive therapy (41). The presence of an anti-troponin I antibody titre ≥1:80 was not associated with the presence of clinical cardiac disease, but was associated with statin therapy status, being less frequent in patients under statin therapy.…”

Section: Renal Transplantationmentioning

confidence: 99%

See 3 more Smart Citations

Anti-cardiac troponin antibodies in clinical human disease: a systematic review

Vilela¹,

Bettencourt‐Silva²,

Costa³

et al. 2017

Ann. Transl. Med.

Self Cite

View full text Add to dashboard Cite

Anti-cardiac troponin antibodies have been studied in different types of clinical diseases and in healthy populations. A systematic review of published data on anti-troponin antibodies was carried out (search performed on PubMed, ISI Web of Knowledge and Scopus databases). From title and abstract analysis, thirty-three articles were included that met the pre-specified criteria; after full-text analysis, nine articles were excluded. Most studies assessed anti-troponin I antibodies. The prevalence of anti-cardiac troponin antibodies in healthy individuals ranged from 0.0% to 20.0%. The prevalence of anti-troponin I autoantibodies in dilated cardiomyopathy (DCM) ranged from 7.0% to 22.2%. Other conditions under study were myocardial infarction, ischemic cardiomyopathy (ICM), peripartum cardiomyopathy (PPCM), Chagas disease, Emery-Dreifuss muscular dystrophy (EDMD) and renal transplantation. In the different patient populations studied, anti-cardiac troponin antibodies have been shown to be either positively or negatively associated with prognostic and clinical features. In what concerns a possible value as biomarkers, these assays have not emerged up to the present moment as important aids for practical clinical decisions in cardiac or other types of patients. In what concerns pathophysiology, anti-cardiac troponin autoantibodies may play a role in different diseases. It can be speculated that these antibodies could be involved in perpetuating some degree of cardiac injury after an event, such as myocardial infarction or PPCM. The major function of the heart is its contractile function, and cardiac muscle contains sarcomeres, which include different types of molecules, of which actin and myosin are essential for strength generation during contraction. Other molecules, such as cardiac troponins, play a role of regulation concerning cardiac muscle contraction. Cardiac troponins I and T have been shown to be different molecules than the corresponding ones in skeletal muscle, and have gained importance as cardiac biomarkers (1,2).Research has shown that antibodies against cardiac troponins exist in different settings, and questions about their role in the cardiovascular pathological continuum have emerged over the last years. The possible role of cardiac troponin autoantibodies in disease processes [and particularly in dilated cardiomyopathy (DCM) and ischemic cardiomyopathy (ICM)] has gained interest (3-6).Animal models in mice have demonstrated that anticardiac troponin I autoantibodies are capable of inducing heart dilatation and dysfunction, apparently through interactions with the calcium balance in cardiomyocytes (7). Okazaki et al. showed that in mice antibodies to cardiac troponin I stained the surface of cardiomyocytes, implying the presence of troponin I on the cell surface (differing from cardiac troponin T) (7). Göser et al. immunized mice with cardiac troponin I, leading to severe inflammation of the myocardium, cardiomegaly, fibrosis and 30% mortality over 270 days (8). However, in a study carri...

show abstract

Section: Discussionmentioning

confidence: 92%

Section: Resultsmentioning

confidence: 99%

Section: Study Limitationsmentioning

confidence: 90%

Section: Renal Transplantationmentioning

confidence: 99%

See 2 more Smart Citations

Anti-cardiac troponin antibodies in clinical human disease: a systematic review

Vilela¹,

Bettencourt‐Silva²,

Costa³

et al. 2017

Ann. Transl. Med.

Self Cite

View full text Add to dashboard Cite

show abstract

“…No trabalho que Nunes et al 9 publicam no presente número da Revista Portuguesa de Cardiologia, uma nova abordagem é dada a esta temática, focando os autores numa população de doentes com fase terminal de doença renal crónica e sujeitos a transplantação renal. Em 2013 este mesmo grupo relatou um caso clínico de uma doente de género feminino com miocardiopatia dilatada e fração de ejeção de 30%, a qual, após transplantação renal, evidenciou uma recuperação da função ventricular, apesar de não ter regredido o seu volume telediastólico 10 .…”

unclassified

Anti-troponin I antibodies in renal transplant patients

Nunes

Sampaio

Cerqueira

et al. 2015

Revista Portuguesa de Cardiologia

Self Cite

View full text Add to dashboard Cite

Disponível na Internet a 2 de fevereiro de 2015A resposta imunitária em situações de agressão ao músculo cardíaco é uma matéria pouco estudada e de resultados práticos pouco relevantes. Mesmo na situação do enfarte do miocárdio, o paradigma da agressão ao miocárdio por razões não infecciosas ou inflamatórias, o impacto clínico dessa investigação é muito reduzido.Um exemplo do que se pode esperar deste tipo de investigação, com potencial reflexo para a atividade clínica, é a recente publicação de um interessante trabalho de Savukoski et al. procurando ensaiar um novo teste laboratorial para determinação de troponina, o qual possa ser livre da interferência de eventuais autoanticorpos antitroponina que possam estar presentes em circulação 1 .A presença destes autoanticorpos específicos foi investigada por este mesmo grupo, o qual demonstrou, numa série de 510 doentes com suspeita de enfarte do miocárdio, a presença de autoanticorpos em 9,2% dos casos, sem contudo se encontrar qualquer reflexo sobre o prognóstico a 12 meses 2 .O aspeto prático desta observação reside no facto de que a presença destes anticorpos pode conduzir a valores falsamente negativos de troponina no soro de doentes com enfarte do miocárdio e desse modo pode contribuir para o atraso no diagnóstico.DOI do artigo original: http://dx.doi.org/10.1016/j.repc.2014.08.018Correio eletrónico: jaraujomorais@mail.telepac.pt A sua presença em indivíduos aparentemente saudáveis também foi relatada. Há alguns anos atrás Adamczyk et al. 3 reportaram uma prevalência de 12,7% de autoanticorpos em indivíduos saudáveis, dadores de sangue, sem diferenças significativas no que respeita às isoformas T ou I.Esta resposta imunitária pode ser parcialmente neutralizada, através da administração por via nasal das três subunidades de troponina (C, I e T) e essa neutralização/vacinação pode ter efeito na redução do tamanho do enfarte, quando a referida administração se processa uma hora antes do fenó-meno isquemia/reperfusão 4 .Um outro campo de interesse e que igualmente tem despertado algum interesse dos investigadores é a presença do mesmo tipo de autoanticorpos em doentes com miocardiopatia dilatada. A distrofia muscular de Emery-Dreifuss é um bom exemplo.Tratando-se de uma doença rara, em alguns casos a doença é detetada através da presença de um quadro de miocardiopatia dilatada, casos estes em que o envolvimento do músculo cardíaco precede o envolvimento dos múscu-los esqueléticos. Num estudo de dez doentes, avaliados em comparação com um grupo de controlo emparelhado para algumas características, foi possível perceber que não há uma relação clara entre níveis de anticorpos e sintomatologia cardíaca, se bem que os autores admitam que a sua deteção pode representar um marcador de previsão de está-dios precoces de miocardiopatia dilatada 5 .A autoimunidade tem o seu lugar na patogénese de algumas entidades como sejam a miocardiopatia dilatada, as http://dx

show abstract

Anti-troponin I antibodies in renal transplant patients

Cited by 2 publications

References 12 publications

Anti-cardiac troponin antibodies in clinical human disease: a systematic review

Anti-cardiac troponin antibodies in clinical human disease: a systematic review

Anti-troponin I antibodies in renal transplant patients

Contact Info

Product

Resources

About